This verifies pathways in cancer (hsa05200), prostate cancer (hsa05215), bladder cancer (hsa05219), pancreatic cancer (hsa05212), the PI3K-Akt signaling pathway (hsa04151), proteoglycans in cancer (hsa05205), and hepatocellular carcinoma (hsa05225). This evidence concerns the gene AKT1 and prostate cancer.